Related Experiment Videos
Severe illness associated with group A-hemolytic streptococcal infections
J C Butler1, B Schwartz, J Kimball
1DOH Bureau of Community Health and Prevention, Centers for Disease Control, Atlanta, GA 30333.
Summary
Severe group A beta-hemolytic streptococcus (GABS) infections can be fatal, particularly in older adults. Early hospitalization may not significantly alter outcomes for these serious GABS infections.
Area of Science:
- Infectious Diseases
- Epidemiology
- Public Health
Background:
- Group A beta-hemolytic streptococcus (GABS) can cause severe, life-threatening infections.
- Surveillance is crucial for understanding the epidemiology and clinical presentation of severe GABS infections.
Purpose of the Study:
- To describe the epidemiologic features and clinical spectrum of severe GABS infections in Wisconsin.
- To identify risk factors and outcomes associated with severe GABS infections.
Main Methods:
- Retrospective case series analysis of severe GABS infections reported to the Wisconsin Division of Health (DOH).
- Inclusion criteria included GABS isolation from blood or specific severe clinical manifestations.
- Data collected on patient demographics, clinical diagnoses, and outcomes.
Main Results:
- Twenty-eight cases of severe GABS infections were reported between November 1989 and October 1990.
- Sepsis and cellulitis were the most common presentations (57% and 50%, respectively).
- The fatality rate was 32%, with older patients (median age 74) more likely to die. Pneumonia and necrotizing fasciitis/myositis were associated with increased mortality.
- The interval from illness onset to hospitalization was similar for fatal and non-fatal cases.
Conclusions:
- Severe GABS infections pose a significant public health threat, with high mortality rates.
- Older age, pneumonia, and necrotizing fasciitis/myositis are associated with increased risk of death.
- Early hospitalization may not be sufficient to improve outcomes, suggesting a need for further research into treatment timing and efficacy.